Tim-wai W. Chan

Kowloon, KKC, Hong Kong Special Administrative Region

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.

Journal: Frontiers in oncology

Published: November 27, 2023

Hong Kong Urological Association-Hong Kong Society of Uro-Oncology consensus statements on the management of advanced prostate cancer-2019 Updates.

Hong Kong Urological Association-Hong Kong Society of Uro-Oncology consensus statements on the management of advanced prostate cancer-2019 Updates.

Journal: Asia-Pacific journal of clinical oncology

Published: April 16, 2021

Prostate cancer management in the era of COVID-19: Recommendations from the Hong Kong Urological Association and Hong Kong Society of Uro-oncology.

Prostate cancer management in the era of COVID-19: Recommendations from the Hong Kong Urological Association and Hong Kong Society of Uro-oncology.

Journal: Asia-Pacific journal of clinical oncology

Published: April 16, 2021

Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.

Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.

Journal: Asia-Pacific journal of clinical oncology

Published: April 16, 2021

Management of advanced prostate cancer in Hong Kong: Insights from an APCCC-Derived survey.

Management of advanced prostate cancer in Hong Kong: Insights from an APCCC-Derived survey.

Journal: Asia-Pacific journal of clinical oncology

Published: October 24, 2019

Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.

Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.

Journal: BJU international

Published: January 18, 2019

Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.

Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.

Journal: Clinical genitourinary cancer

Published: May 16, 2018

Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.

Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.

Journal: BJU international

Published: December 07, 2017

Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.

Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.

Journal: BMC urology

Published: September 04, 2015

Showing 1-9 of 9

Last Updated: 09/26/2026